Cagrilintide
Cagrilintide is a peptide built to mimic amylin, a hormone the body naturally releases alongside insulin that plays a role in appetite and fullness. It's designed to last much longer in the body than natural amylin, and it's one of the more extensively studied compounds in current metabolic research.
- Sequence
- Modified 37-amino acid analog of human amylin
- Format
- Lyophilized powder
- Half-Life
- Long-acting; roughly 6 to 8 days reported in study models
What Is Cagrilintide?
Cagrilintide is a synthetic analog of amylin, a hormone released from the same pancreatic cells that release insulin. Natural amylin plays a role in signaling fullness after eating, but it doesn't last long in the body, which limited its usefulness as a research and development target for years.
To get around that, Cagrilintide was built with a fatty acid chain attached to its structure, a modification that allows it to bind reversibly to albumin in the blood and stay active for days instead of minutes. This design also improves its physical stability, since natural amylin has a tendency to clump together in a way that made it difficult to work with in earlier research.
What Cagrilintide Is Being Researched For
Appetite and Food Intake
The core research focus on Cagrilintide is how it interacts with amylin receptors in the brain to influence appetite and food intake signaling.[1][2]
Body Weight and Fat Mass
Research in both animal models and human trials has looked at how Cagrilintide affects body weight, with studies specifically tracking changes in fat mass relative to lean mass.[2]
Combination Research with GLP-1 Compounds
A significant portion of current research pairs Cagrilintide with GLP-1 receptor agonists like semaglutide, studying whether the two mechanisms produce a more complete signal than either compound alone.
How Cagrilintide Works
Activating Amylin Receptors
Research points to Cagrilintide binding to amylin receptors in the brain, particularly in an area involved in processing signals related to fullness and food intake. Studies have found this activation depends specifically on two receptor subtypes, known as AMY1R and AMY3R.[2]
Extending Its Time in the Body
Research points to the fatty acid modification on Cagrilintide allowing it to bind reversibly to albumin in the bloodstream, which slows how quickly it's cleared and is part of why it can be studied on a much less frequent dosing schedule than natural amylin.[1]
Reconstitution and Handling
Cagrilintide is typically supplied as a lyophilized powder in a sealed vial and reconstituted with bacteriostatic water before use in a research setting. Water should be added slowly rather than injected directly into the powder, and the vial should be swirled, not shaken.
Since the amount of water used affects the concentration of the final solution, researchers often use a dosage calculator to work this out before mixing. Once reconstituted, the solution is kept refrigerated to help preserve its stability.
Key Takeaways
Cagrilintide stands out from many research peptides in that it has a genuine body of published human trial data, largely because of active pharmaceutical development around amylin-based obesity research. Its core mechanism centers on amylin receptor activation tied to appetite and food intake signaling, with a design specifically built to extend its activity far beyond natural amylin's short window. Much of the current research examines it in combination with GLP-1 receptor agonists rather than as a standalone compound.
Frequently Asked Questions
What Is Cagrilintide Derived From?
It's a synthetic analog of amylin, a hormone the body naturally releases from the pancreas alongside insulin.
How Is Cagrilintide Different from Semaglutide?
They work through different receptor systems. Cagrilintide acts on amylin receptors, while semaglutide acts on GLP-1 receptors. The two are often studied together because their mechanisms are considered complementary.
Has Cagrilintide Been Tested in Humans?
Yes. Unlike many research peptides, Cagrilintide has been studied in published human clinical trials, including trials evaluating it alongside semaglutide.
Why Does Cagrilintide Last Longer in the Body Than Natural Amylin?
It's built with a fatty acid chain that allows it to bind reversibly to albumin in the blood, which slows how quickly the body clears it.
Sources and Research
- Kruse T, Hansen JL, Dahl K, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021;64(15):11183-11194.
- Carvas AO, Leuthardt A, Kulka P, et al. Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. EBioMedicine. 2025;118:105836.
For educational and research purposes only. Not medical advice. Always consult a licensed healthcare professional before starting any protocol.